ibudilast has been researched along with Nerve Pain in 4 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 5.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| "Ibudilast (AV-411) is a non-selective phosphodiesterase inhibitor that is also known to suppress glial cell activation." | 2.44 | Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. ( Hutchinson, MR; Johnson, KW; Ledeboer, A; Watkins, LR, 2007) |
| "Ibudilast is a phosphodiesterase inhibitor with anti-inflammatory activity, but its effect on activated microglia in chronic neuropathic pain is poorly understood." | 1.48 | Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline. ( Asaki, T; Fujita, M; Hasegawa, M; Omachi, S; Rokushima, M; Sakaguchi, G; Shinohara, S; Tamano, R; Yogo, E; Yoneda, S, 2018) |
| " The markedly delayed efficacy of all 3 glial modulatory drugs may prove instructive for interpretation of apparent drug failures after shorter dosing regimens." | 1.40 | Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain. ( Ellis, A; Falci, S; Favret, J; Johnson, KW; Maier, SF; Rice, KC; Watkins, LR; Wieseler, J, 2014) |
| "Ibudilast treatment did not significantly alter this increase." | 1.38 | The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain. ( Broadhead, A; Hama, AT; Lorrain, DS; Sagen, J, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, M | 1 |
| Tamano, R | 1 |
| Yoneda, S | 1 |
| Omachi, S | 1 |
| Yogo, E | 1 |
| Rokushima, M | 1 |
| Shinohara, S | 1 |
| Sakaguchi, G | 1 |
| Hasegawa, M | 1 |
| Asaki, T | 1 |
| Ellis, A | 1 |
| Wieseler, J | 1 |
| Favret, J | 1 |
| Johnson, KW | 2 |
| Rice, KC | 1 |
| Maier, SF | 1 |
| Falci, S | 1 |
| Watkins, LR | 2 |
| Hama, AT | 1 |
| Broadhead, A | 1 |
| Lorrain, DS | 1 |
| Sagen, J | 1 |
| Ledeboer, A | 1 |
| Hutchinson, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Full-Factorial, Parallel-Group Study Evaluating Safety and Efficacy of Naltrexone-Acetaminophen Combination in Acute Migraine Treatment in Adults, With Exploratory Focus on Co-Occurring[NCT05685225] | Phase 2 | 300 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for ibudilast and Nerve Pain
| Article | Year |
|---|---|
Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2007 |
3 other studies available for ibudilast and Nerve Pain
| Article | Year |
|---|---|
Ibudilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: Different inhibitory mechanism on spinal microglia from minocycline and propentofylline.
Topics: Animals; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Hyperalgesia; Injections, Spin | 2018 |
Systemic administration of propentofylline, ibudilast, and (+)-naltrexone each reverses mechanical allodynia in a novel rat model of central neuropathic pain.
Topics: Animals; Disease Models, Animal; Hyperalgesia; Male; Naltrexone; Narcotic Antagonists; Neuralgia; Ne | 2014 |
The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain.
Topics: Analgesics; Animals; Anti-Asthmatic Agents; Central Nervous System Diseases; Male; Neuralgia; Neurog | 2012 |